
    
      This study is an extended study of KSTHD_FURESTEM-CD phase 1 / 2a clinical trials in patients
      with moderate active Crohn's disease who had received at least once a FURESTEM-CD injection.
      The purpose of this clinical trial is to evaluate long-term safety and efficacy in patients
      for approximately 36 months (144 weeks).
    
  